This year's Paris Course on Revascularization (PCR) had many sessions focusing on future therapies and technologies based on vulnerable plaque and angiogenesis. But, not surprisingly, with European commercialization a year old and US marketing just beginning, drug-eluting stents (DES) dominated the discussions, as interventional cardiologists on the podium and in the audience debated how extensively to incorporate the new devices into their everyday practices. And, just as expectedly, enthusiasm about the clinical value of the new stents was almost evenly balanced with concerns about larger societal—read, economic--concerns.
To some degree, the timing of PCR made it an appropriate forum to recap much of the clinical trial work...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?